| Literature DB >> 26294967 |
Marlieke Visser1, Hans W M Niessen2, Wouter E M Kok3, Riccardo Cocchieri4, Willem Wisselink5, Paul A M van Leeuwen5, Bas A J M de Mol4.
Abstract
Major surgery induces a long fasting time and provokes an inflammatory response which increases the risk of infections. Nutrition given before and during surgery can avoid fasting and has been shown to increase the arginine/asymmetric dimetlhylarginine ratio, a marker of nitric oxide availability, in cardiac tissue and increased concentrations of branched chain amino acids in blood plasma. However, the effect of this new nutritional strategy on organ inflammatory response is unknown. Therefore, we studied the effect of nutrition before and during cardiac surgery on myocardial inflammatory response. In this trial, 32 patients were randomised between enteral, parenteral, and no nutrition supplementation (control) from 2 days before, during, up to 2 days after coronary artery bypass grafting. Both solutions included proteins or amino acids, glucose, vitamins, and minerals. Myocardial atrial tissue was sampled before and after revascularization and was analysed immunohistochemically, subdivided into cardiomyocytic, fatty, and fibrotic areas. Inflammatory cells, especially leukocytes, were present in cardiac tissue in all study groups. No significant differences were found in the myocardial inflammatory response between the enteral, parenteral, and control groups. In conclusion, nutrition given before and during surgery neither stimulates nor diminishes the myocardial inflammatory response in patients undergoing coronary artery bypass grafting. The trial was registered in Netherlands Trial Register (NTR): NTR2183.Entities:
Year: 2015 PMID: 26294967 PMCID: PMC4532862 DOI: 10.1155/2015/123158
Source DB: PubMed Journal: J Nutr Metab ISSN: 2090-0724
Composition of enteral and parenteral nutrition.
| Enteral group | Parenteral group | ||
|---|---|---|---|
| Drink (at home) | Nutrition (at hospital) | Nutrition (at hospital) | |
| Volume (mL) | 125 | 1050 | 1250 |
| Amino acids (g) | 12 | 80.5 | 40 |
| Carbohydrates (g) | 37.1 | 95 | 80 |
| Fat (g) | 11.6 | 1.5 | 50 |
| Energy (kcal) | 300 | 745 | 955 |
| Vitamins and minerals | Yes | Yes | Yes |
Inflammatory cells in the 1st and 2nd myocardial tissue samples (number/mm2) in study groups.
| Start of surgery (1st tissue sample) | End of surgery (2nd tissue sample) | |||||
|---|---|---|---|---|---|---|
| Enteral group ( | Parenteral group ( | Control group ( | Enteral group ( | Parenteral group ( | Control group ( | |
| Lymphocytes (CD45) | ||||||
| Cardiomyocytic area | 5.03 | 0.00 | 10.23 | 5.75 | 3.92 | 1.91 |
| Fibrotic area ( | 154.10 | 93.90 | 241.18 | 178.09 | 47.39 | 60.25 |
| Fatty area | 8.54 | 4.06 | 6.22 | 3.22 | 2.56 | 7.24 |
| Neutrophil granulocytes (MPO) | ||||||
| Cardiomyocytic area | 0.00 | 0.00 | 1.47 | 4.10 | 3.07 | 0.65 |
| Fibrotic area | 0.00 | 0.00 | 0.00 | 0.00 | 6.72 | 1.64 |
| Fatty area | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Macrophages (CD68) | ||||||
| Cardiomyocytic area | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fibrotic area | 0.00 | 0.00 | 1.72 | 0.00 | 0.72 | 2.11 |
| Fatty area | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| IL-6 | ||||||
| Cardiomyocytic area | 28.72 | 0.00 | 19.20 | 36.03 | 20.53 | 14.53 |
| Fibrotic area | 0.00 | 0.00 | 2.47 | 0.00 | 0.00 | 0.00 |
| Fatty area | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| IL-1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 |
| TNF- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Activated endothelium | ||||||
| P-selectin | 2.17 | 1.41 | 3.37 | 2.29 | 3.33 | 1.70 |
| E-selectin | 0.00 | 0.00 | 0.00 | 0.17 | 0.14 | 0.00 |
| Proinflammatory vessel damage (CML) | 26.00 | 20.78 | 46.31 | 28.78 | 21.18 | 21.21 |
| C3d | ||||||
| Endothelium | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Erythrocytes intensity score > 1 | 41.7% | 22.2% | 9.1% | 58.3% | 44.4% | 27.3% |
| Fibrotic area intensity score > 1 | 8.3% | 11.1% | 9.1% | 75.0% | 55.6% | 54.5% |
Values are median (IQR).
MPO, myeloperoxidase; CML, carboxymethyl lysine.
Patient characteristics and postoperative outcome.
| Enteral group ( | Parenteral group ( | Control group ( | |
|---|---|---|---|
| Patients | |||
| Age (years) | 66.1 ± 6.1 | 66.6 ± 7.1 | 63.3 ± 6.7 |
| Gender (% male) | 12 (100) | 10 (100) | 11 (100) |
| BMI (kg/m2) | 27.8 | 27.4 | 27.7 |
| Fat-free mass index (kg/m2) | 19.8 | 19.5 | 20.9 |
| Diabetes mellitus (%) | 3 (25.0) | 4 (44.4) | 3 (27.3) |
| EuroSCORE | 2.0 | 3.0 | 2.0 |
| Previous acute myocardial infarction (%) | 5 (41.7) | 6 (66.7) | 2 (18.2) |
| Preoperative laboratory tests | |||
| Plasma CRP (mg/L) | 0.8 | 2.7 | 0.6 |
| Plasma albumin (g/L) | 46.5 | 43.0 | 46.0 |
| Plasma NT-proBNP (ng/L) | 234 | 204 | 99 |
| Intraoperative period | |||
| Propofol use (%) | 8 (66.7) | 4 (44.4) | 8 (72.7) |
| Surgery duration (min) | 268 ± 39 | 279 ± 27 | 294 ± 40 |
| Postoperative period | |||
| Plasma CK-MB ( | 9.0 | 8.2 | 10.3 |
| Intensive care stay (hours) | 21.5 | 24.0 | 21.0 |
| Stent (%) | 0 (0) | 0 (0) | 0 (0) |
| Catheterisation < 3 months (%) | 0 (0) | 0 (0) | 1 (9.1) |
| Revascularisation < 3 months (%) | 0 (0) | 0 (0) | 0 (0) |
| Infections < 3 months (%) | 0 (0) | 0 (0) | 1 (9.1) |
| Mortality (%) | 0 (0) | 0 (0) | 0 (0) |
Values are expressed as median (IQR) or mean ± SD. EuroSCORE, European System for Cardiac Operation Risk Evaluation score. The EuroSCORE is a validated risk stratification system to determine the risk profile for mortality of cardiothoracic surgery patients [13].